PT - JOURNAL ARTICLE AU - Abe, Soichiro AU - Inoue, Manabu AU - Shirakawa, Manabu AU - Uchida, Kazutaka AU - Yamada, Kiyofumi AU - Kuramoto, Yoji AU - Namitome, Satoshi AU - Shindo, Seigo AU - Sakakibara, Fumihiro AU - Kouno, Junichi AU - Tatebayashi, Kotaro AU - Kinjo, Norito AU - Tsuji, Shoichiro AU - Tanada, Shuichi AU - Beppu, Mikiya AU - Matsukawa, Hidetoshi AU - Ihara, Masafumi AU - Yoshimura, Shinichi TI - Computed tomography perfusion parameters predictive of symptomatic intracranial hemorrhage after mechanical thrombectomy in patients with cerebral large vessel occlusion AID - 10.1101/2023.02.16.23286072 DP - 2023 Jan 01 TA - medRxiv PG - 2023.02.16.23286072 4099 - http://medrxiv.org/content/early/2023/02/23/2023.02.16.23286072.short 4100 - http://medrxiv.org/content/early/2023/02/23/2023.02.16.23286072.full AB - Background Hemorrhagic transformation (HT) after recanalization is a severe complication in patients with a large ischemic core due to cerebral large vessel occlusion. Risk assessment using perfusion imaging to predict hemorrhagic infarction has not been established. Thus, we aimed to investigate the association between perfusion imaging findings and HT in patients with acute cerebral large vessel occlusion who had undergone preoperative perfusion imaging evaluation and mechanical thrombectomy.Methods We enrolled consecutive patients who received mechanical thrombectomy (MT) after undergoing perfusion imaging for anterior large vessel occlusion from May 2019 to March 2022. The patients in whom recanalization was not achieved and who experienced procedure-related bleeding were excluded. We investigated the predictors of symptomatic intracranial hemorrhage (sICH) by exploring preoperative perfusion imaging parameters [relative cerebral blood flow, relative cerebral blood volume (rCBV), time of maximum concentration, hypoperfusion index ratio].Results Among the 167 patients (median age 79 years, 47% female) enrolled, 63 (38%) and 14 (8%) patients had any intracranial hemorrhage and sICH (sICH group), respectively. The sICH group had a shorter puncture-recanalization time than the non-sICH group (median [interquartile range (IQR)]; 43 [34–55] vs. 61 [37–88], p = 0.046), whereas the modified Rankin Scale at 90 days showed a worse prognosis (median [IQR]; 5 [5–6] vs 3 [1–4], p<0.01). All perfusion imaging parameters were significantly predicting the sICH group in multiple logistic regression analysis. The value of rCBV was the parameter most strongly associated with sICH in receiver operating characteristic curve analysis (area under the curve = 0.90, 95% confidence interval [0.83–0.98]; cutoff 43 ml; sensitivity, 86 %; specificity, 87%).Conclusion Among perfusion CT parameters, rCBV is highly associated with sICH after MT for cerebral large vessel occlusion. In patients with low rCBV regions, the indication of mechanical thrombectomy should be carefully considered for postoperative intracranial hemorrhage.Clinical perspectiveOf the various parameters assessed via perfusion CT, the value of rCBV demonstrates a strong correlation with the occurrence of symptomatic intracranial hemorrhage following mechanical thrombectomy for cerebral anterior large vessel occlusion.When treating patients with regions of large low-rCBV, it is important to carefully determine the indication of mechanical due to the potential risk of postoperative intracranial hemorrhage.Competing Interest StatementDr. Inoue reports the lecturer's fees from Bayer, Bristol-Myers Squibb. Dr. Uchida received lecturer's fees from Daiichi Sankyo. H. Matsukawa received a lecture fee from Daiichi-Sankyo and consulting services fee from B. Braun. Dr. Yoshimura reports personal fees from Boehringer-Ingelheim, Daiichi-Sankyo, Bayer, Termo, Medtronic, Kaneka Medics, Johnson & Johnson Health Care Systems Inc, Stryker, and BMS. The other authors report no conflicts. All other authors declared no conflicts of interest.Funding StatementNone.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Hyogo medical university IRBI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableThe data supporting this study's findings can be accessed from the corresponding author upon reasonable request.ICHintracranial hemorrhageAUCarea under the curvea-sICHasymptomatic intracranial hemorrhageCEcardiac embolismHThemorrhagic transformationHIRhypoperfusion intensity ratioIQRinterquartile rangeLAAlarge-artery atherosclerosisNIHSSNational Institutes of Health Stroke ScaleMTmechanical thrombectomymRSmodified Rankin ScalemTICImodified Thrombolysis in Cerebral InfarctionRCTsrandomized controlled trialsROCreceiver operating characteristicsrCBFrelative cerebral blood flowrCBVrelative cerebral blood volumeTmaxtime of maximum concentrationTOASTTrial of Org 10172 in Acute Stroke TreatmentsICHsymptomatic intracranial hemorrhage